close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Atea Pharmaceuticals, Inc. - common stock (NQ:AVIR)

3.185 -0.005 (-0.16%)
Streaming Delayed Price Updated: 2:41 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Atea Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 5 Next >
Atea (AVIR) Q2 Loss Narrows 8%
Via The Motley Fool
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Top movers in Wednesday's pre-market session
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
Atea Pharma Cuts Workforce By 25%, Expects $15 Million In Cost Savings, Plans Phase 3 Hepatitis C Trial
Atea Pharma posted a Q4 loss of $0.40 per share, cut 25% of its workforce, and is launching a Phase 3 HCV trial while facing analyst skepticism over its drug. 
Via Benzinga
After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study
Atea Pharmaceuticals reports 98% SVR12 in a Phase 2 hepatitis C study, supporting an eight-week treatment plan with bemnifosbuvir and ruzasvir. 
Via Benzinga
Recap: Atea Pharmaceuticals Q4 Earnings
 
Via Benzinga
Atea Pharmaceuticals Earnings Preview
 
Via Benzinga
Atea Pharmaceuticals's Earnings Outlook
 
Via Benzinga
Earnings Preview For Atea Pharmaceuticals
 
Via Benzinga
Earnings Scheduled For March 6, 2025
 
Via Benzinga
Earnings Preview: Atea Pharmaceuticals
 
Via Benzinga
Preview: Atea Pharmaceuticals's Earnings
 
Via Benzinga
Atea Pharma's Investigational Dengue Treatment Fast Tracked In US
 
Via Benzinga
Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus
Atea Pharmaceuticals' Phase 3 SUNRISE-3 trial for bemnifosbuvir in COVID-19 patients did not meet the primary endpoint. The company remains focused on its hepatitis C combination therapy. 
Via Benzinga
Adobe, SelectQuote, Similarweb And Other Big Stocks Moving Lower In Friday's Pre-Market Session
 
Via Benzinga
Atea Pharmaceuticals Shares Promising Data From Therapy Study For Hepatitis C Virus
Atea Pharmaceuticals announces 97% SVR12 in Phase 2 HCV study of bemnifosbuvir. Data shows high efficacy, safety, and low resistance risk. 
Via Benzinga
AVIR Stock Earnings: Atea Pharmaceuticals Misses EPS for Q1 2024
AVIR stock results show that Atea Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
5 Under 10: Low Share Price, Debt Free, Lots Of Cash
A look at five low-priced stocks with lots of cash per share, and no or very low debt. Most of them have very low-cap stocks and should be considered very speculative. 
Via Talk Markets
Atea Pharmaceuticals To Advance Global Late-Stage COVID-19 Study of Bemnifosbuvir
 
Via Benzinga
Atea Pharmaceuticals' Hepatitis C Virus Candidate Shows Efficacy
Atea Pharmaceuticals Inc (NASDAQ: AVIR) reported initial data from the first 52 patients in the lead-in cohort of its Phase 2 combination eight-week study of bemnifosbuvir and ruzasvir (RZR) for 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
 
Via Benzinga
Skyline Champion, Atea Pharmaceuticals And Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded mixed, with the Dow Jones dropping over 100 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Why Nvidia Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers QualTek Services Inc. (NASDAQ: QTEK) shares jumped 127.2% to $0.1740 after dropping around 21% on Friday. Qualtek Services recently filed voluntarily petitions for Chapter 11 bankruptcy. 
Via Benzinga
Biotech Bargain Hunt: Concentra Biosciences Eyes Atea's Promising COVID-19 Response
Earlier today, Concentra Biosciences, an affiliate of Tang Capital, sent an acquisition proposal to Atea Pharmaceuticals Inc (NASDAQ: AVIR) at $5.75 per share, representing a 55% premium to Friday’s... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Why ZIM Integrated Shipping Services Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Greenhill & Co., Inc. (NYSE: GHL) shares jumped 116.4% to $14.67 after Mizuho announced it would acquire the company for $15 per share. 
Via Benzinga
US Stocks Mixed; Nordic American Tankers Posts Upbeat Results
U.S. stocks traded mixed this morning, with the Dow Jones trading slightly lower on Monday. Following the market opening Monday, the Dow traded down 0.01% to 33,422.94 while the NASDAQ rose 0.09% to... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday, 79 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 35 stocks hit new 52-week lows. 
Via Benzinga
Atea Pharmaceuticals Earnings Preview
Atea Pharmaceuticals (NASDAQ:AVIR) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that Atea... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today